Outcome | Follow-up period | BMI (kg/m2) | Unadjusted HR (95% CI) | Adjusted HR (95% CI) |
---|---|---|---|---|
Breast cancer specific death | 0-10 | <25 | 1.00 | 1.00 |
25-29 | 0.90 (0.70, 1.16) | 0.98 (0.74, 1.30) | ||
30+ | 0.97 (0.76, 1.25) | 1.10 (0.82, 1.46) | ||
Whole study period | <25 | 1.00 | 1.00 | |
25-29 | 0.90 (0.70, 1.15) | 0.97 (0.73, 1.29) | ||
30+ | 0.95 (0.74, 1.22) | 1.06 (0.80, 1.41) | ||
Overall mortality | 0-10 | <25 | 1.00 | 1.00 |
25-29 | 0.88 (0.71, 1.09) | 1.03 (0.82, 1.30) | ||
30+ | 0.91 (0.74, 1.12) | 0.96 (0.75, 1.22) | ||
Whole study period | <25 | 1.00 | 1.00 | |
25-29 | 0.88 (0.72, 1.08) | 1.01 (0.81, 1.26) | ||
30+ | 0.93 (0.76, 1.14) | 0.96 (0.76, 1.21) | ||
Death from other/unknown causes | 0-10 | <25 | 1.00 | 1.00 |
25-29 | 0.87 (0.59, 1.28) | 0.97 (0.66, 1.45) | ||
30+ | 0.79 (0.53, 1.17) | 0.84 (0.55, 1.29) | ||
Whole study period | <25 | 1.00 | 1.00 | |
25-29 | 0.89 (0.62, 1.27) | 0.98 (0.68, 1.41) | ||
30+ | 0.90 (0.63, 1.29) | 0.96 (0.65, 1.42) | ||
Loco-regional recurrence | 0-5 | <25 | 1.00 | 1.00 |
25-29 | 0.85 (0.42, 1.71) | 0.80 (0.39, 1.67) | ||
30+ | 1.57 (0.85, 2.87) | 1.82 (0.95, 3.48) | ||
Whole study period | <25 | 1.00 | 1.00 | |
25-29 | 0.76 (0.40, 1.44) | 0.74 (0.38, 1.44) | ||
30+ | 1.35 (0.77, 2.34) | 1.48 (0.81, 2.68) | ||
Distant metastasis | 0-5 | <25 | 1.00 | 1.00 |
25-29 | 0.95 (0.62, 1.46) | 0.94 (0.60, 1.47) | ||
30+ | 1.15 (0.76, 1.75) | 1.27 (0.81, 1.97) | ||
Whole study period | <25 | 1.00 | 1.00 | |
25-29 | 1.12 (0.77, 1.62) | 1.08 (0.74, 1.59) | ||
30+ | 1.33 (0.92, 1.91) | 1.35 (0.92, 1.98) |